Jakob Lindberg has followed and led major parts of Oncopeptides’ journey – as CEO when he joined in 2011, later as Chief Science Officer, and today as a scientific advisor.
It is a journey that began in a small, unmanned room at the Karolinska Institute with a promising discovery on how to improve a class of chemotherapy called alkylating agents. This path took him through one of the most extraordinary episodes in Swedish biotech history: the withdrawal of the company’s drug from the US market and a simultaneous European approval – based on the exact same data.
What has he learned along the way? How does he view Oncopeptides’ position today, in the midst of a rapidly changing myeloma landscape? And what will it take for the company to succeed moving forward – not least with its new brain tumor program?
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
